Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.59 |
| ▸ | NOS1 | P29475 | 8/20 | 0.59 |
| ▸ | NOS2 | P35228 | 8/20 | 0.59 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833200 | 0.89 | NOS3 (0.61) | NOS3NOS1NOS2MCHR1SLC6A4 | |
| SCHEMBL5833679 | 0.85 | NOS3 (0.57) | NOS3NOS1NOS2FEN1IKBKB | |
| SCHEMBL5833741 | 0.81 | NOS3 (0.63) | NOS3NOS1NOS2 | |
| SCHEMBL5833610 | 0.80 | NOS3 (0.73) | NOS3NOS1NOS2MCHR1 | |
| SCHEMBL5833782 | 0.80 | NOS3 (0.60) | NOS3NOS1NOS2 | |
| SCHEMBL5833614 | 0.77 | NOS3 (0.49) | NOS3NOS1NOS2FEN1IKBKB | |
| SCHEMBL5833938 | 0.77 | NOS3 (0.64) | NOS3NOS1NOS2FEN1PIM1 | |
| SCHEMBL5663413 | 0.77 | IRAK4 (0.47) | FEN1IKBKBCHUKPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL5662379 | 0.76 | IRAK4 (0.46) | FEN1IKBKBCHUKPIM1PIM2 | |
| SCHEMBL5833762 | 0.74 | NOS3 (1.00) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS3 2/4885NOS1 1/4885NOS2 3/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS3 2/4885NOS1 1/4885NOS2 6/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.